Litcius/Paper detail

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Chan Y. Cheah, Michael C. Wei, Shen Yin, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Nancy L. Bartlett

2022The Lancet Oncology436 citationsDOIOpen Access PDF

Topics & Concepts

MedicineFollicular lymphomaRefractory (planetary science)Internal medicineClinical endpointProgressive diseaseCD20Follicular phaseLymphomaOncologyRituximabPhases of clinical researchGastroenterologyChemotherapyClinical trialBiologyAstrobiologyCAR-T cell therapy researchLymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research